Ipsen execs juggling 'too many' pipeline projects

(fiercebiotech) - Ipsen CEO Jean-Luc Belingard is plagued by the abundance of promising drugs in his pipeline.

"We have enough products in early development, we may even have too many," he tells Bloomberg in an interview. And, he adds with similar Gallic flair, his cancer therapies "are prompting regular approaches from others in the field but for now we have turned a deaf ear."....

Lire la suite de l'article sur fiercebiotech